APOE and COMT polymorphisms are complementary biomarkers of status, stability, and transitions in normal aging and early mild cognitive impairment

Frontiers in Aging Neuroscience

Volumn 6, Issue SEP, 2014, Pages

  Dixon, Roger A ^a   DeCarlo, Correne A ^b   MacDonald, Stuart W S ^b   Vergote, David ^c   Jhamandas, Jack ^a   Westaway, David ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

APOE; BDNF; COMT; Mild cognitive impairment; Victoria longitudinal study

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE;

ADULT; AGED; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DNA POLYMORPHISM; FEMALE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84907178290     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00236     Document Type: Article

References (76)

1. Albert, M. S., DeKoskey, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease. Alzheimers Dement. 7, 270-279. doi: 10.1016/j.jalz.2011.03.008
2. Anstey, K. J. (2014). Optimizing cognitive development over the life course and preventing cognitive decline: introducing the Cognitive Health Environment Life Course Model (CHELM). Int. J. Behav. Dev. 38, 1-10. doi: 10.1177/0165025413512255
3. Anstey, K. J., Cherbuin, N., Eramudugolla, R., Sargent-Cox, K., Easteal, S., Kumar, R., et al. (2013). Characterizing mild cognitive disorders in the young-old over 8 years: prevalence, estimated incidence, stability of diagnosis, and impact on IADLs. Alzheimers Dement. 9, 640-648. doi: 10.1016/j.jalz.2012.11.013
4. Barabash, A., Marcos, A., Anci´n, I., Vazquez-Alvarez, B., de Ugarte, C., Gil, P., et al. (2009). APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease. Neurobiol. Aging 30, 1254-1264. doi: 10.1016/j.neurobiolaging.2007.11.003
5. Barnett, J. H., Scoriels, L., and Munafo, M. R. (2008). Meta-analysis of the cognitive effects of the Catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol. Psychiatry 64, 137-144. doi: 10.1016/j.biopsych.2008.01.005
6. Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., and Tanzi, R. E. (2007). Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39, 17-23. doi: 10.1038/ng1934
7. Blom, E. S., Giedraitis, V., Zetterberg, H., Fukumoto, H., Blennow, K., Hyman, B. T., et al. (2009). Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement. Geriatr. Cogn. Disord. 27, 458-464. doi: 10.1159/000216841
8. Brainerd, C. J., Reyna, V. F., Petersen, R. C., Smith, G. E., and Taub, E. S. (2011). Is the Apolipoprotein e genotype a biomarker for mild cognitive impairment? Findings from a nationally representative study. Neuropsychology 25, 679-689. doi: 10.1037/a0024483
9. Brodaty, H., Heffernan, M., Kochan, N. A., Draper, B., Trollar, J. N., Reppermund, S., et al. (2013). Mild cognitive impairment in a community sample: the Sydney memory and ageing study. Alzheimers Dement. 9, 310-317. doi: 10.1016/j.jalz.2011.11.010
10. Bruder, G. E., Keilp, J. G., Xu, H., Shikhman, M., Schori, E., Gorman, J. M., et al. (2005). Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol. Psychiatry 58, 901-907. doi: 10.1016/j.biopsych.2005.05.010
11. Caselli, R. J., Locke, D. E. C., Dueck, A. C., Knopman, D. S., Woodruff, B. K., Hoffman-Snyder, C., et al. (2014). The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimers Dement. 10, 84-92. doi: 10.1016/j.jalz.2013.01.004
12. Caselli, R. J., Reiman, E. M., Locke, D. E., Hutton, M. L., Hentz, J. G., Hoffman-Snyder, C., et al. (2007). Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch. Neurol. 64, 1306-1311. doi: 10.1001/archneur.64.9.1306
13. Cathomas, F., Vogler, C., Euler-Sigmund, J. C., de Quervain, D. J., and Papassotiropoulos, A. (2010). Fine-mapping of the Brain-derived neurotrophic factor (BDNF) gene supports an association of the Val66Met polymorphism with episodic memory. Int. J. Neuropsychopharmacol. 13, 975-980. doi: 10.1017/S1461145710000519
14. Davies, G., Harris, S. E., Reynolds, C. A., Payton, A., Knight, H. M., Liewald, D. C., et al. (2014). A genome-wide association study implicates the APOE locus in nonpathological cognitive aging. Mol. Psychiatry 19, 76-87. doi: 10.1038/mp.2012.159
15. de Frias, C. M., Dixon, R. A., and Strauss, E. (2009). Characterizing executive functioning in older special populations: from cognitively elite to cognitively impaired. Neuropsychology 23, 778-791. doi: 10.1037/a0016743
16. Dixon, R. A., and de Frias, C. M. (2004). The victoria longitudinal study: from characterizing cognitive aging to illustrating changes in memory compensation. Aging Neuropsychol. Cogn. 11, 346-376. doi: 10.1080/13825580490511161
17. Dixon, R. A., and de Frias, C. M. (2014). Cognitively elite, cognitively normal, and cognitively impaired aging: neurocognitive status and stability moderate memory performance. J. Clin. Exp. Neuropsychol. 36, 418-430. doi: 10.1080/13803395.2014.903901
18. Dixon, R. A., Garrett, D. D., Lentz, T. L., MacDonald, S. W. S., Strauss, E., and Hultsch, D. F. (2007). Neurocognitive markers of cognitive impairment: exploring the roles of speed and inconsistency. Neuropsychology 21, 381-399. doi: 10.1037/0894-4105.21.3.381
19. Dixon, R. A., Small, B. J., MacDonald, S. W. S., and McArdle, J. J. (2012). "Yes, memory declines with aging-but when, how, and why?," in Memory and aging, eds M. Naveh-Benjamin and N. Ohta (New York, NY: Psychology Press), 325-347.
20. Dixon, R. A., Wahlin, A˚., Maitland, S. B., Hultsch, D. F., Hertzog, C., and Ba¨ckman, L. (2004). Episodic memory change in late adulthood: generalizability across samples and performance indices. Mem. Cogn. 32, 768-778. doi: 10.3758/BF03195867
21. Dolcos, S., MacDonald, S. W. S., Braslavsky, A., Camicioli, R., and Dixon, R. A. (2012). Mild cognitive impairment is associated with selected functional markers: integrating concurrent, longitudinal, and stability effects. Neuropsychology 26, 209-223. doi: 10.1037/a0026760
22. Ekstrom, R. B., French, J. E. W., Harman, H. H., and Dermen, D. (1976). Manual for the Kit of Factor-Referenced Cognitive Tests. Princeton, NJ: Educational Testing Service.
23. Elias-Sonnenschein, L. S., Viechtbauer, W., Ramakers, I. H., Verhey, F. R., and Visser, P. J. (2011). Predictive value of APOE-epsilon4 allele for progression from MCI to AD-type dementia: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 82, 1149-1156. doi: 10.1136/jnnp.2010.231555
24. Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Ojopi, E. B., Talib, L. L., Mendonca, V. A., et al. (2010). Effect of Brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J. Biol. Psychiatry 11, 774-780. doi: 10.3109/15622971003797241
25. Fotuhi, M., Hachinski, V., and Whitehouse, P. J. (2009). Changing perspectives regarding late-life dementia. Nat. Rev. Neurol. 5, 649-658. doi: 10.1038/nrneurol.2009.175
26. Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., et al. (2006). Mild cognitive impairment. Lancet 367, 1262-1270. doi: 10.1016/S0140-6736(06)68542-5
27. Geda, Y. E., and Nedelska, Z. (2012). Mild cognitive impairment: a subset of minor neurocognitive disorder? Am. J. Geriatr. Psychiatry 20, 821-826. doi: 10.1097/JGP.0b013e31826abc00
28. Golde, T. E., Schneider, L. S., and Koo, E. H. (2011). Anti-Aß therapeutics in Alzheimer's disease: the need for a new paradigm shift. Neuron 69, 203-213. doi: 10.1016/j.neuron.2011.01.002
29. Harris, S. E., and Deary, I. J. (2011). The genetics of cognitive ability and cognitive ageing in healthy older people. Trends Cogn. Sci. 15, 388-394. doi: 10.1016/j.tics.2011.07.004
30. Hashimoto, R., Hirata, Y., Asada, T., Yamashita, F., Nemoto, K., Mori, T., et al. (2009). Effect of the Brain-derived neurotrophic factor and the Apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease. Genes Brain Behav. 8, 43-52. doi: 10.1111/j.1601-183X.2008.00440.x
31. Hultsch, D. F., Hertzog, C., Dixon, R. A., and Small, B. J. (1998). Memory Change in the Aged. New York, NY: Cambridge University Press.
32. Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., and Langa, K. M. (2013). Monetary costs of dementia in the United States. N. Engl. J. Med. 368, 1326-1334. doi: 10.1056/NEJMsa1204629
33. Izaks, G. J., Gansevoort, R. T., van der Knaap, A. M., Navis, G., Dullaart, R. P. F., and Slaets, J. P. J. (2011). The association of APOE genotype with cognitive function in persons aged 35 years or older. PLoS ONE 6:e27415. doi: 10.1371/journal.pone.0027415
34. Jorm, A. F., Mather, K. A., Butterworth, P., Anstey, K. J., Christensen, H., and Easteal, S. (2007). APOE genotype and cognitive functioning in a large age-stratified population sample. Neuropsychology 21, 1-8. doi: 10.1037/0894-4105.21.1.1
35. Josefsson, M., de Luna, X., Pudas, S., Nilsson, L.-G., and Nyberg, L. (2012). Genetic and lifestyle predictors of 15-year longitudinal change in episodic memory. J. Am. Geriatr. Soc. 60, 2308-2312. doi: 10.1111/jgs.12000
36. Koepsell, T. D., and Monsell, S. E. (2012). Reversion from mild cognitive impairment to normal or near-normal cognition. Neurology 79, 1591-1598. doi: 10.1212/WNL.0b013e31826e26b7
37. Kozauer, N. A., Mielke, M. M., Chan, G. K. C., Rebok, G. W., and Lyketsos, C. G. (2008). Apolipoprotein E genotype and lifetime cognitive decline. Int. Psychogeriatr. 20, 109-123. doi: 10.1017/S104161020700587X
38. Kryscio, R. J., Schmitt, F. A., Salazar, J. C., Mendiondo, M. S., and Markesbery, W. R. (2006). Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 66, 828-832. doi: 10.1212/01.wnl.0000203264.71880.45
39. Lane, R., Feldman, H. H., Meyer, J., He, Y., Ferris, S. H., Nordberg, A., et al. (2008). Synergistic effect of Apolipoprotein E epsilon4 and Butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet. Genomics 18, 289-298. doi: 10.1097/FPC.0b013e3282f63f29
40. Lanni, C., Garbin, G., Lisa, A., Biundo, F., Ranzenigo, A., Sinforiani, E., et al. (2012). Influence of COMT Val58Met polymorphism on Alzheimer's disease and mild cognitive impairment in Italian patients. J. Alzheimers Dis. 32, 919-926. doi: 10.1017/S104161020700587X
41. Laukka, E. J., Lo¨vde´n, M., Herlitz, A., Karlsson, S., Ferencz, B., Pantzar, A., et al. (2013). Genetic effects on old-age cognitive functioning: a population-based study. Psychol. Aging 28, 262-274. doi: 10.1037/a0030829
42. Lin, P.-J., and Neumann, P. J. (2013). The economics of mild cognitive impairment. Alzheimers Dement. 9, 58-62. doi: 10.1016/j.jalz.2012.05.2117
43. Lindenberger, U., Nagel, I. E., Chicherio, C., Li, S.-C., Keekeren, H. R., and Ba¨ckman, L. (2008). Age-related decline in brain resources modulates genetic effects on cognitive functioning. Front. Neurosci. 2, 234-244. doi: 10.3389/neuro.01.039.2008
44. Liu, F., Pardo, L. M., Schuur, M., Sanchez-Juan, P., Isaacs, A., Sleegers, K., et al. (2010). The Apolipoprotein E gene and its age-specific effects on cognitive function. Neurobiol. Aging 31, 1831-1833. doi: 10.1016/j.neurobiolaging.2008.09.015
45. Luciano, M., Batty, G. D., McGilchrist, M., Linksted, P., Fitzpatrick, B., Jackson, C., et al. (2010). Shared genetic aetiology between cognitive ability and cardiovascular disease risk factors: generation Scotland's Scottish family health study. Intelligence 38, 304-313. doi: 10.1016/j.intell.2010.03.002
46. MacDonald, S. W. S., Hultsch, D. F., Strauss, E., and Dixon, R. A. (2003). Age-related slowing of digit symbol substitution revisited: what do longitudinal age changes reflect? J. Gerontol. B Psychol. Sci. Soc. Sci. 58, P187-P194. doi: 10.1093/geronb/58.3.P187
47. Mandelman, S. D., and Grigorenko, E. L. (2012). BDNF Val66Met and cognition: All, none, or some? A meta-analysis of the genetic association. Genes Brain Behav. 11, 127-136. doi: 10.1111/j.1601-183X.2011.00738.x
48. Martinez, M. F., Martin, X. E., Alcelay, L. G., Flores, J. C., Valiente, J. M., Juanbeltz, B. I., et al. (2009). The COMT Val158 met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers. BMC Neurosci. 10:125. doi: 10.1186/1471-2202-10-125
49. McFall, G. P., Wiebe, S. A., Vergote, D., Jhamandas, J., Westaway, D., and Dixon, R. A. (2014). IDE (rs6583817) polymorphism and pulse pressure are independently and interactively associated with level and change in executive function in older adults. Psychol. Aging 29, 418-430. doi: 10.1037/a0034656
50. McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R. Jr. Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269. doi: 10.1016/j.jalz.2011.03.005
51. Miyajima, F., Ollier, W., Mayes, A., Jackson, A., Thacker, N., Rabbitt, P., et al. (2008). Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities of the elderly. Genes Brain Behav. 7, 411-417. doi: 10.1111/j.1601-183X.2007.00363.x
52. Palmer, K., Wang, H. X., Ba¨ckman, L., Winblad, B., and Fratiglioni, L. (2002). Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. Am. J. Psychiatry 159, 436-442. doi: 10.1176/appi.ajp.159.3.436
53. Payton, A. (2006). Investigating cognitive genetics and its implications for the treatment of cognitive deficit. Genes Brain Behav. 5(Suppl. 1), 44-53. doi: 10.1111/j.1601-183X.2006.00194.x
54. Payton, A. (2009). The impact of genetic research on our understanding of normal cognitive ageing: 1995 to 2009. Neuropsychol. Rev. 19, 451-477. doi: 10.1007/s11065-009-9116-z
55. Petersen, R. C., and Knopman, D. S. (2006). MCI is a clinically useful concept. Int. Psychogeriatr. 18, 394-402. doi: 10.1017/S1041610206003929
56. Plassman, B. L., Williams, J. W., Burke, J. R., Holsinger, T., and Benjamin, S. (2010). Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann. Intern. Med. 153, 182-193. doi: 10.7326/0003-4819-153-3-201008030-00258
57. Reinvang, I., Deary, I. J., Fjell, A. M., Steen, V. M., Espeseth, T., and Parasuraman, R. (2010). Neurogenetic effects on cognition in aging brains: a window of opportunity for intervention? Front. Aging Neurosci. 2:143. doi: 10.3389/fnagi.2010.00143
58. Reinvang, I., Espeseth, T., and Westlye, L. T. (2013). APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. Neurosci. Biobehav. Rev. 37, 1322-1335. doi: 10.1016/j.neubiorev.2013.05.006
59. Risacher, S. L., Kim, S., Shen, L., Nho, K., Faroud, T., Green, R. C., et al. (2013). The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front. Aging Neurosci. 5:11. doi: 10.3389/fnagi.2013.00011
60. Ritchie, K., Artero, S., and Touchon, J. (2001). Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 56, 37-42. doi: 10.1212/WNL.56.1.37
61. Rowe, J. B., Hughes, L., Williams-Gray, C. H., Bishop, S., Fallon, S., Barker, R. A., et al. (2010). The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease. Neurobiol. Aging 31, 1064-1068. doi: 10.1016/j.neurobiolaging.2008.07.009
62. Sapkota, S., Vergote, D., Westaway, D., Jhamandas, J., and Dixon, R. A. (2014). Synergistic associations of catechol-O-methyltransferase and brain-derived neurotrophic factor with executive function in aging are selective and modified by apolipoprotein E. Neurobiol. Aging. doi: 10.1016/j.neurobiolaging.2014.06.020. [Epub ahead of print].
63. Savitz, J., Solms, M., and Ramesar, R. (2006). The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav. 5, 311-328. doi: 10.1111/j.1601-183X.2005.00163.x
64. Schiepers, O. J. G., Harris, S. E., Gow, A. J., Pattie, A., Brett, C. E., Starr, J. M., et al. (2012). APOE ε4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921. Mol. Psychiatry 17, 315-324. doi: 10.1038/mp.2010.137
65. Small, B. J., Rosnick, C. B., Fratiglioni, L., and Ba¨ckman, L. (2004). Apolipoprotein E and cognitive performance: a meta-analysis. Psychol. Aging 19, 592-600. doi: 10.1037/0882-7974.19.4.592
66. Sperling, R. A., Karlawish, J., and Johnson, K. A. (2013). Preclinical Alzheimer's disease: the challenges ahead. Nat. Rev. Neurol. 9, 54-58. doi: 10.1038/nrneurol.2012.241
67. Tapia-Arancibia, L., Aliaga, E., Silhol, M., and Arancibia, S. (2008). New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res. Rev. 59, 201-220. doi: 10.1016/j.brainresrev.2008.07.007
68. Thurstone, T. G. (1962). Primary Mental Abilities: Grades 9-12, 1962 Revision. Chicago, IL: Science Research Associates.
69. Vandermorris, S., Hultsch, D. F., Hunter, M. A., MacDonald, S. W. S., and Strauss, E. (2011). Including persistency of impairment in mild cognitive impairment classification enhances prediction of 5-year decline. Arch. Clin. Neuropsychol. 26, 26-37. doi: 10.1093/arclin/acq093
70. Wechsler, D. (1981). WAIS-R Manual. New York, NY: Psychological Corporation.
71. Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.-O., et al. (2004). Mild cognitive impairment-beyond controversies, towards a consensus. Report of the International Working Group on Mild Cognitive Impairment. J. Int. Med. 256, 240-246. doi: 10.1111/j.1365-2796.2004.01380.x
72. Wisdom, N. M., Callahan, J. L., and Hawkins, K. A. (2011). The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol. Aging 32, 63-74. doi: 10.1016/j.neurobiolaging.2009.02.003
73. Wishart, H. A., Roth, R. M., Saykin, A. J., Rhodes, C. H., Tsongalis, G. J., Pattin, K. A., et al. (2011). COMT Val158Met genotype and individual differences in executive function in healthy adults. J. Int. Neuropsychol. Soc. 17, 174-180. doi: 10.1017/S1355617710001402
74. Woodard, J. L., Sugarman, M. A., Nielson, K. A., Smith, J. C., Seidenberg, M., Durgerian, S., et al. (2012). Lifestyle and genetic contributions to cognitive decline and hippocampal structure and function in healthy aging. Curr. Alzheimer Res. 9, 436-446. doi: 10.2174/156720512800492477
75. Yarnell, A. J., Breen, D. P., Duncan, D. P., Khoo, T. K., Coleman, S. Y., Firbank, M. J., et al. (2014). Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study. Neurology 82, 308-316. doi: 10.1212/WNL.0000000000000066
76. Zheng, J., Dixon, R. A., and Li, L. (2012). Development of isotope labelling LC-MS for human salivary metabolomics and application to profiling metabolome changes associated with mild cognitive impairment. Anal. Chem. 84, 10802-10811. doi: 10.1021/ac3028307